Literature DB >> 1679547

Mu-opioid-receptor-mediated inhibition of the N-type calcium-channel current.

E Seward1, C Hammond, G Henderson.   

Abstract

The predominant consequences of mu-opioid-receptor activation are depression of both neuronal activity and transmitter release. Mu-Opioid agonists have previously been observed to increase a potassium conductance and to inhibit adenylate cyclase. We now report that activation of mu-opioid receptors directly decreases the N-type calcium-channel current in a differentiated, human neuroblastoma cell line (SH-SY5Y). The coupling between the mu-opioid receptor and the calcium channel involves a pertussis toxin-sensitive G protein and is independent of changes in adenylate cyclase activity. The inhibition of the calcium-channel current is voltage dependent because it is largely overcome by strong membrane depolarization. It is not associated with changes in the kinetics of current inactivation. Therefore, the mu-receptor belongs to the superfamily of G-protein-coupled, inhibitory neurotransmitter receptors which modulate the activity of calcium and potassium channels and adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679547     DOI: 10.1098/rspb.1991.0061

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  29 in total

Review 1.  Calcium channel functions in pain processing.

Authors:  John Park; Z David Luo
Journal:  Channels (Austin)       Date:  2010-11-01       Impact factor: 2.581

2.  Kappa-opioid receptor activation modulates Ca2+ currents and secretion in isolated neuroendocrine nerve terminals.

Authors:  K I Rusin; D R Giovannucci; E L Stuenkel; H C Moises
Journal:  J Neurosci       Date:  1997-09-01       Impact factor: 6.167

Review 3.  Calcium signalling through L-type calcium channels: role in pathophysiology of spinal nociceptive transmission.

Authors:  Olivier Roca-Lapirot; Houda Radwani; Franck Aby; Frédéric Nagy; Marc Landry; Pascal Fossat
Journal:  Br J Pharmacol       Date:  2017-03-24       Impact factor: 8.739

4.  The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line.

Authors:  M Connor; A Yeo; G Henderson
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

5.  Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex.

Authors:  Joel M Brittain; Djane B Duarte; Sarah M Wilson; Weiguo Zhu; Carrie Ballard; Philip L Johnson; Naikui Liu; Wenhui Xiong; Matthew S Ripsch; Yuying Wang; Jill C Fehrenbacher; Stephanie D Fitz; May Khanna; Chul-Kyu Park; Brian S Schmutzler; Bo Myung Cheon; Michael R Due; Tatiana Brustovetsky; Nicole M Ashpole; Andy Hudmon; Samy O Meroueh; Cynthia M Hingtgen; Nickolay Brustovetsky; Ru-Rong Ji; Joyce H Hurley; Xiaoming Jin; Anantha Shekhar; Xiao-Ming Xu; Gerry S Oxford; Michael R Vasko; Fletcher A White; Rajesh Khanna
Journal:  Nat Med       Date:  2011-06-05       Impact factor: 53.440

6.  Direct interaction of gbetagamma with a C-terminal gbetagamma-binding domain of the Ca2+ channel alpha1 subunit is responsible for channel inhibition by G protein-coupled receptors.

Authors:  N Qin; D Platano; R Olcese; E Stefani; L Birnbaumer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 7.  Functional analysis of cloned opioid receptors in transfected cell lines.

Authors:  E T Piros; T G Hales; C J Evans
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

Review 8.  A Biased View of μ-Opioid Receptors?

Authors:  Alexandra E Conibear; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

9.  mu-Opioid peptides inhibit thalamic neurons.

Authors:  J Brunton; S Charpak
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

10.  Mechanism of mu-opioid receptor-mediated presynaptic inhibition in the rat hippocampus in vitro.

Authors:  M Capogna; B H Gähwiler; S M Thompson
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.